Related Experiment Video

Updated: Jul 13, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Pneumonia, pneumocystis pneumonia]

Ryuji Koike1, Masayoshi Harigai

  • 1Clinical Research Center, Tokyo Medical and Dental University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 24, 2007
PubMed

Insights

Patients with rheumatoid arthritis (RA) on anti-tumor necrosis factor (TNF) agents face high risks of pneumonia. Identifying risk factors like age and comorbidities may help reduce serious infections in these patients.

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) patients on anti-tumor necrosis factor (TNF) agents are at high risk for serious adverse events, particularly pneumonia.
  • Bacterial pneumonia and Pneumocystis jirovecii pneumonia are significant concerns in this patient population.
  • Postmarketing surveillance in Japan identified Pneumocystis jirovecii as a key causal agent.

Purpose of the Study:

  • To identify and analyze predictable risk factors for pneumonia in RA patients undergoing anti-TNF therapy.
  • To evaluate the synergistic impact of identified risk factors on pneumonia incidence.

Main Methods:

  • Analysis of postmarketing all-patients registration surveillance data from Japan.
  • Statistical extraction of risk factors associated with pneumonia development.

Main Results:

  • Older age, pulmonary comorbidities, and diabetes mellitus were identified as independent risk factors for pneumonia.
  • The dosage of co-prescribed glucocorticoids also emerged as a significant risk factor.
  • These factors were found to contribute both respectively and synergistically to pneumonia risk.

Conclusions:

  • Considering identified risk factors such as age, comorbidities, and glucocorticoid dosage may help mitigate the incidence of bacterial and Pneumocystis pneumonia in RA patients treated with anti-TNF agents.
  • Proactive risk assessment can potentially improve patient safety during anti-TNF therapy.

More Related Videos

Experimental Model to Evaluate Resolution of Pneumonia09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: